BioSpace News Archive

Pfizer Inc. announced positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and older with moderate to severe atopic dermatitis (AD).

ArQule, Inc. announced that Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 at 9:30 a.m. PT at the Beverly Hilton in Beverly Hills, CA.

Omeros Corporation today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week.

Seven presentations will be shared, including new data on the risks of long-term cardiovascular, renal and infection complications, underlining Takeda’s commitment to further understanding of this rare disease

Sensorion announced that the independent Data Safety Monitoring Board has undertaken a review of the safety data for the 76 first patients having completed the phase 2 clinical trial for SENS-111 in the treatment of acute unilateral vestibulopathy.

GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported a first set of results from Week 96 of the REVERSE Phase III clinical trial.

IBM and Neurorehabilitation Center ERGO Aktiv put together a virtual assistant for families dealing with situation after a stroke or other acquired brain damage.

InteRNA Technologies announced today the recent publication of data from a collaboration with University Medical Center (UMC) Utrecht in Journal of Neuroscience showing that the downregulation of miR-135a levels can reduce seizure activity after the onset of spontaneous recurrent seizures (SRS) in chronic-stage Mesial Temporal Lobe Epilepsy (mTLE) in mouse models

China Pharma Holdings, Inc. announced financial results for the quarter ended March 31, 2019.

Acquisition expands Ginkgo’s biological codebase for organism engineering for the production of natural product pharmaceuticals